Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00844168 · ClinicalTrials.gov registry record · Phase 1
Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant
A Phase 1 study of Advanced Adult Primary Liver Cancer and Localized Unresectable Adult Primary Liver Cancer, sponsored by University of Washington.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT00844168 is a Phase 1 study of Advanced Adult Primary Liver Cancer and Localized Unresectable Adult Primary Liver Cancer that has completed, run by University of Washington. The registered enrollment target is 4 participants, below the 30-participant average among 7 other Advanced Adult Primary Liver Cancer trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00844168, a Phase 1 study of Advanced Adult Primary Liver Cancer and Localized Unresectable Adult Primary Liver Cancer, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects and best dose of sorafenib tosylate in treating patients with liver cancer who have undergone a liver transplant. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sorafenib after liver transplant may be an effective treatment for liver cancer
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG sorafenib tosylate
Study Locations (1)
Washington
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2009-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00844168
The ClinicalTrials.gov registry entry for NCT00844168 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 30-participant average among 7 other Advanced Adult Primary Liver Cancer trials with a reported enrollment target (87% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Advanced Adult Primary Liver Cancer appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00844168 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT00844168 about?
NCT00844168 is a clinical study titled "Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant". This phase I trial studies the side effects and best dose of sorafenib tosylate in treating patients with liver cancer who have undergone a liver transplant. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the...
What is the current status of trial NCT00844168?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2009-01.
What conditions does trial NCT00844168 study?
This clinical trial studies the following conditions: Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer, Adult Primary Hepatocellular Carcinoma, Localized Resectable Adult Primary Liver Cancer.
What interventions are being tested in trial NCT00844168?
The interventions under investigation include: laboratory biomarker analysis (OTHER), sorafenib tosylate (DRUG).
Who is sponsoring clinical trial NCT00844168?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00844168 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Adult Primary Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
COMPLETED · Phase 1
-
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
COMPLETED · Phase 1
-
Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction
COMPLETED · Phase 1
-
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
COMPLETED · Phase 1
-
TSR-022 (anti-TIM-3 Antibody) and TSR-042 (anti-PD-1 Antibody) in Patients with Liver Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT
ACTIVE NOT RECRUITING
Explore more on PlainTrial
Advanced Adult Primary Liver Cancer
All registered trials for this condition
Localized Unresectable Adult Primary Liver Cancer
All registered trials for this condition
Washington
All trials with a study site in Washington
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.